大麻医薬品の世界市場規模、シェア、成長分析、ブランド別-産業予測、2024～2031年

世界の大麻医薬品市場規模は2022年に15億米ドルと評価され、2023年の24億3,000万米ドルから2031年には1,152億7,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは62％で成長する展望です。

さまざまな医療領域で大麻が広く使用されていることが、市場拡大の大きな促進要因となっています。大麻ベースの製品は、関節炎、がん、パーキンソン病、アルツハイマー病などの慢性疾患や、うつ病、てんかん、不安などの神経疾患を含む、さまざまな病気の管理に有効であることがますます認識されるようになっています。これらの化合物は患者の疼痛を緩和する上で重要な役割を果たしており、疼痛管理における大麻ベースの医薬品の需要拡大に寄与しています。米国、英国、カナダなど多くの国々で治療目的の大麻が合法化されたことは、その治療特性を受け入れる方向への世界のシフトを反映しており、市場の成長を後押ししています。米国のMORE法のような立法的イニシアチブは、大麻合法化に対する政府の支持をさらに示すものであり、世界中で同様の動きに火をつけています。政府と消費者が大麻をますます受け入れるようになるにつれて、医療専門家は大麻療法を処方に組み込むようになり、市場拡大にさらに拍車をかけています。このような世界の受容と医療統合の動向は、大麻医薬品市場が当面持続的な成長を遂げることを意味しています。

目次

エグゼクティブサマリー

• 市場概要
• 繁栄と衰退

調査手法

• 情報調達
• セカンダリとプライマリデータソース
• 市場規模の推定
• 市場の前提条件と制限

親市場の分析

• 市場概要
• 市場規模
• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリクス
• パイプライン製品の分析
• マクロ経済指標
• 主要投資の分析
• 主要成功要因
• 競合の程度

市場力学と展望

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制情勢
• ポーターの分析
• 将来の混乱についての特別な考察

大麻医薬品の世界市場：ブランド別

• 市場概要
• エピディオレックス
• サティベックス

大麻医薬品の世界市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主要市場企業が採用した戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• Pharmaceutical Group（英国）
• MedReleaf Australia（オーストラリア）
• Aurora Cannabis（カナダ）
• GW Pharmaceuticals（英国）
• Clever Leaves（Colombia）
• Cannabis Europa（英国）
• Tilray（カナダ）
• Aphria Inc.（カナダ）
• Panaxia Pharmaceuticals（イスラエル）
• Aphria Inc.（カナダ）
• Cresco Labs（米国）
• Canopy Growth Corporation（カナダ）
• Cronos Group Inc.（カナダ）
• Green Thumb Industries Inc.（米国）
• Charlotte's Web Holdings, Inc.（米国）
• Harvest Health & Recreation Inc.（米国）
• TerrAscend Corp.（カナダ）
• Trulieve Cannabis Corp.（米国）
• Acreage Holdings, Inc.（米国）
• Curaleaf Holdings, Inc.（米国）

Global Cannabis Pharmaceuticals Market size was valued at USD 1.5 billion in 2022 and is poised to grow from USD 2.43 billion in 2023 to USD 115.27 billion by 2031, growing at a CAGR of 62% in the forecast period (2024-2031).

The extensive use of cannabis across various medical domains serves as a significant driver for market expansion. Cannabis-based products are increasingly recognized for their efficacy in managing a spectrum of illnesses, including chronic conditions like arthritis, cancer, Parkinson's, and Alzheimer's disease, as well as neurological disorders such as depression, epilepsy, and anxiety. These compounds play a crucial role in alleviating patient pain, contributing to the growing demand for cannabis-based medications in pain management. The legalization of cannabis for therapeutic purposes in numerous countries, including the US, UK, Canada, and others, reflects a global shift towards acceptance of its therapeutic properties, propelling market growth. Legislative initiatives such as the MORE Act in the US further signify governmental support for cannabis legalization, igniting similar movements worldwide. As governments and consumers increasingly embrace cannabis, healthcare professionals are integrating cannabis therapies into their prescriptions, further fueling market expansion. This evolving trend towards global acceptance and medical integration positions the cannabis market for sustained growth in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cannabis Pharmaceuticals Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cannabis Pharmaceuticals Market Segmental Analysis

The global cannabis pharmaceuticals market is segmented into epidiolex and sativex on the basis of brand. If the market is divided based on region, we end up with the following segments: North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Cannabis Pharmaceuticals Market

A significant catalyst for growth in the cannabis pharmaceutical market is the increasing trend of legalizing medical cannabis in various regions, bolstering the market's potential as more areas embrace its medicinal use. Moreover, the rising acceptance of medical cannabis among patients seeking treatment for conditions like epilepsy, cancer, and chronic pain reflects a positive shift in perceptions, driving continued market expansion. Additionally, the prevalence of chronic diseases treatable with cannabis-based pharmaceuticals, such as multiple sclerosis, depression, and anxiety disorders, contributes to market growth.

Restraints in the Cannabis Pharmaceuticals Market

Challenges persist, including regulatory variations across regions and the need for more robust clinical evidence to establish efficacy and safety. Furthermore, lingering misconceptions and social stigma surrounding cannabis use may deter some healthcare providers and patients from considering cannabis-based treatments, potentially impeding adoption rates.

Market Trends of the Cannabis Pharmaceuticals Market

key market trends such as the diversification of product formats, pharmaceutical partnerships, and advancements in extraction technologies are poised to drive further innovation and growth in the cannabis pharmaceutical sector.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Cannabis Pharmaceuticals Market by Brand

• Market Overview
• Epidiolex
• Sativex

Global Cannabis Pharmaceuticals Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pharmaceutical Group (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MedReleaf Australia (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurora Cannabis (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GW Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clever Leaves (Colombia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cannabis Europa (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tilray (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aphria Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panaxia Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aphria Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cresco Labs (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canopy Growth Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cronos Group Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Thumb Industries Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charlotte's Web Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harvest Health & Recreation Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TerrAscend Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trulieve Cannabis Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acreage Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curaleaf Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments